Key issues in the clinical management of gastrointestinal stromal tumors: An expert discussion

Robert G. Maki, Jean Yves Blay, George D. Demetri, Jonathan A. Fletcher, Heikki Joensuu, Javiermart In-Broto, Toshirou Nishida, Peter Reichardt, Patrick Schöffski, Jonathan C. Trent

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.

Original languageEnglish (US)
Pages (from-to)823-830
Number of pages8
Issue number7
StatePublished - Jun 12 2015
Externally publishedYes


  • Carney-Stratakis syndrome
  • GIST
  • Gastrointestinal stromal tumor
  • Imatinib
  • KIT
  • Regorafenib
  • SDH
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Key issues in the clinical management of gastrointestinal stromal tumors: An expert discussion'. Together they form a unique fingerprint.

Cite this